QQQ   350.21 (-1.30%)
AAPL   178.07 (-0.64%)
MSFT   324.36 (-2.79%)
META   266.55 (-1.69%)
GOOGL   122.93 (-3.44%)
AMZN   122.65 (-3.13%)
TSLA   226.22 (+2.22%)
NVDA   381.41 (-1.33%)
NIO   7.76 (-1.52%)
BABA   85.46 (-1.43%)
AMD   119.64 (-3.69%)
T   15.94 (+1.72%)
F   13.47 (+4.18%)
MU   67.32 (-0.33%)
CGC   0.73 (-1.01%)
GE   106.54 (+1.02%)
DIS   92.53 (+0.40%)
AMC   4.69 (+1.08%)
PFE   38.86 (+1.28%)
PYPL   64.07 (-1.46%)
NFLX   402.68 (+0.85%)
QQQ   350.21 (-1.30%)
AAPL   178.07 (-0.64%)
MSFT   324.36 (-2.79%)
META   266.55 (-1.69%)
GOOGL   122.93 (-3.44%)
AMZN   122.65 (-3.13%)
TSLA   226.22 (+2.22%)
NVDA   381.41 (-1.33%)
NIO   7.76 (-1.52%)
BABA   85.46 (-1.43%)
AMD   119.64 (-3.69%)
T   15.94 (+1.72%)
F   13.47 (+4.18%)
MU   67.32 (-0.33%)
CGC   0.73 (-1.01%)
GE   106.54 (+1.02%)
DIS   92.53 (+0.40%)
AMC   4.69 (+1.08%)
PFE   38.86 (+1.28%)
PYPL   64.07 (-1.46%)
NFLX   402.68 (+0.85%)
QQQ   350.21 (-1.30%)
AAPL   178.07 (-0.64%)
MSFT   324.36 (-2.79%)
META   266.55 (-1.69%)
GOOGL   122.93 (-3.44%)
AMZN   122.65 (-3.13%)
TSLA   226.22 (+2.22%)
NVDA   381.41 (-1.33%)
NIO   7.76 (-1.52%)
BABA   85.46 (-1.43%)
AMD   119.64 (-3.69%)
T   15.94 (+1.72%)
F   13.47 (+4.18%)
MU   67.32 (-0.33%)
CGC   0.73 (-1.01%)
GE   106.54 (+1.02%)
DIS   92.53 (+0.40%)
AMC   4.69 (+1.08%)
PFE   38.86 (+1.28%)
PYPL   64.07 (-1.46%)
NFLX   402.68 (+0.85%)
QQQ   350.21 (-1.30%)
AAPL   178.07 (-0.64%)
MSFT   324.36 (-2.79%)
META   266.55 (-1.69%)
GOOGL   122.93 (-3.44%)
AMZN   122.65 (-3.13%)
TSLA   226.22 (+2.22%)
NVDA   381.41 (-1.33%)
NIO   7.76 (-1.52%)
BABA   85.46 (-1.43%)
AMD   119.64 (-3.69%)
T   15.94 (+1.72%)
F   13.47 (+4.18%)
MU   67.32 (-0.33%)
CGC   0.73 (-1.01%)
GE   106.54 (+1.02%)
DIS   92.53 (+0.40%)
AMC   4.69 (+1.08%)
PFE   38.86 (+1.28%)
PYPL   64.07 (-1.46%)
NFLX   402.68 (+0.85%)
NASDAQ:ACIU

AC Immune (ACIU) Competitors

$2.26
-0.05 (-2.16%)
(As of 01:37 PM ET)
Compare
Today's Range
$2.25
$2.31
50-Day Range
$1.85
$2.39
52-Week Range
$1.68
$3.90
Volume
20,596 shs
Average Volume
123,118 shs
Market Capitalization
$188.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

ACIU vs. CUE, IMMP, SELB, KNTE, AKBA, FULC, MACK, ADCT, ZVRA, and CTXR

Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Cue Biopharma (CUE), Immutep (IMMP), Selecta Biosciences (SELB), Kinnate Biopharma (KNTE), Akebia Therapeutics (AKBA), Fulcrum Therapeutics (FULC), Merrimack Pharmaceuticals (MACK), ADC Therapeutics (ADCT), Zevra Therapeutics (ZVRA), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical preparations" industry.

AC Immune vs.

AC Immune (NASDAQ:ACIU) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.

AC Immune has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500.

AC Immune currently has a consensus target price of $13.00, suggesting a potential upside of 475.22%. Cue Biopharma has a consensus target price of $8.33, suggesting a potential upside of 123.41%. Given AC Immune's higher possible upside, equities research analysts plainly believe AC Immune is more favorable than Cue Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AC Immune
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cue Biopharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Cue Biopharma had 3 more articles in the media than AC Immune. MarketBeat recorded 3 mentions for Cue Biopharma and 0 mentions for AC Immune. AC Immune's average media sentiment score of 1.32 beat Cue Biopharma's score of 0.45 indicating that AC Immune is being referred to more favorably in the media.

Company Overall Sentiment
AC Immune Positive
Cue Biopharma Neutral

Cue Biopharma has lower revenue, but higher earnings than AC Immune. Cue Biopharma is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AC Immune$4.12 million45.83-$74.14 million-$0.88-2.57
Cue Biopharma$1.25 million129.19-$53.01 million-$1.34-2.79

16.8% of AC Immune shares are held by institutional investors. Comparatively, 31.9% of Cue Biopharma shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 10.2% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AC Immune has a net margin of 0.00% compared to Cue Biopharma's net margin of -12,005.79%. AC Immune's return on equity of -38.85% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
AC Immune N/A -38.85% -35.71%
Cue Biopharma -12,005.79% -89.72% -62.11%

AC Immune received 112 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 62.50% of users gave AC Immune an outperform vote while only 50.92% of users gave Cue Biopharma an outperform vote.

CompanyUnderperformOutperform
AC ImmuneOutperform Votes
250
62.50%
Underperform Votes
150
37.50%
Cue BiopharmaOutperform Votes
138
50.92%
Underperform Votes
133
49.08%

Summary

AC Immune beats Cue Biopharma on 10 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACIU vs. The Competition

MetricAC ImmunePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$188.82M$5.85B$4.54B$6.22B
Dividend YieldN/A2.60%5.94%6.49%
P/E Ratio-2.574.5795.7511.98
Price / Sales45.83329.273,488.5088.39
Price / CashN/A18.8891.28104.76
Price / Book1.074.794.705.28
Net Income-$74.14M$191.86M$117.17M$192.53M
7 Day Performance3.67%6.24%4.57%4.75%
1 Month Performance8.39%4.65%2.88%5.72%
1 Year Performance-33.53%16.15%11.80%1.53%

AC Immune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CUE
Cue Biopharma
2.4187 of 5 stars
$4.11
+5.1%
$8.33
+102.8%
-0.8%$177.46M$432,227.00-3.0757News Coverage
Positive News
Gap Up
IMMP
Immutep
1.4506 of 5 stars
$2.01
-5.6%
$10.00
+397.5%
-18.4%$176.74M$4.90M0.002,021
SELB
Selecta Biosciences
2.4207 of 5 stars
$1.15
+9.5%
$6.00
+421.7%
+40.2%$176.44M$110.78M-12.7858News Coverage
Positive News
KNTE
Kinnate Biopharma
2.6853 of 5 stars
$3.78
+1.3%
$17.25
+356.3%
-46.6%$176.04MN/A-1.3661
AKBA
Akebia Therapeutics
2.3375 of 5 stars
$0.96
-15.1%
$2.00
+108.6%
+214.4%$178.23M$292.60M-3.09426Gap Up
High Trading Volume
FULC
Fulcrum Therapeutics
2.254 of 5 stars
$2.89
-0.7%
$10.00
+246.0%
-58.2%$178.48M$4.05M-1.28104
MACK
Merrimack Pharmaceuticals
0 of 5 stars
$12.52
+0.2%
N/A+140.0%$178.54MN/A-104.33426Positive News
ADCT
ADC Therapeutics
1.8766 of 5 stars
$2.28
flat
$10.17
+345.9%
-63.7%$175.13M$209.91M-0.90312
ZVRA
Zevra Therapeutics
1.791 of 5 stars
$5.06
+0.4%
$12.00
+137.2%
N/A$174.77M$10.46M-3.40N/APositive News
CTXR
Citius Pharmaceuticals
1.8205 of 5 stars
$1.10
-0.9%
$6.00
+445.5%
+36.5%$174.74MN/A-5.5015Positive News

Related Companies and Tools

This page (NASDAQ:ACIU) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -